SCHEMBL10189356

SCHEMBL10189356

COCCOCCC(=O)Nc1cc(-c2cnsc2-c2cc(C)c(C)c(OC)c2)ccc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.41
MAPT P10636 3/20 0.36
THRB P10828 1/20 0.36
TDP1 Q9NUW8 3/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
LTB4R Q15722 1/20 0.35
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
CYP2C9 P11712 2/20 0.35
MEN1 O00255 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 2/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 2/20 0.34
POLQ O75417 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189470 0.90 PDE4B (0.36) POLBMAPTALDH1A1KMT2AKDM4E
SCHEMBL619438 0.90 POLB (0.43) POLBMAPTTDP1GAAL3MBTL1
SCHEMBL10189358 0.88 NPSR1 (0.46) POLBMAPTTHRBTDP1GAA
SCHEMBL10189353 0.88 LTB4R (0.39) POLBMAPTTHRBTDP1GAA
SCHEMBL10189355 0.88 HDAC1 (0.40) POLBMAPTTHRBTDP1GAA
SCHEMBL10189362 0.88 ALDH1A1 (0.38) POLBMAPTL3MBTL1NPSR1ALDH1A1
SCHEMBL10189354 0.86 EGFR (0.42) POLBMAPTTHRBTDP1GAA
SCHEMBL10188926 0.83 ALDH1A1 (0.44) POLBMAPTGAANPSR1ALDH1A1
SCHEMBL12338823 0.83 POLB (0.41) POLBMAPTTHRBTDP1GAA
SCHEMBL10189364 0.82 ALDH1A1 (0.40) POLBTDP1GAAL3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 POLB 223/4885MAPT 95/4885THRB 1189/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 POLB 223/4885MAPT 95/4885THRB 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.